Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers
  • 4.9 (64)
  • Medicine

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

  1. 2d ago ·  Video

    ESMO 2026 GU Highlights VOLGA, DASL-HiCAP, PROTEUS, KEYNOTE-564, LITESPARK-011

    Welcome to the Oncology Brothers podcast! In this episode, we were joined by Drs. Shilpa Gupta and Ashish Kamat, to discuss the latest updates from ESMO 2026 in Madrid. With nearly 40,000 attendees and thousands of abstracts presented, we focus on the most impactful findings in genitourinary (GU) oncology.   Episode Highlights: Muscle-Invasive Bladder Cancer (MIBC): A deep dive into the VOLGA trial, exploring the efficacy of neoadjuvant therapy with durvalumab and enfortumab vedotin (EV) in MIBC. We discussed the implications of reduced toxicity and potential changes to standard care. Non-Muscle-Invasive Bladder Cancer (NMIBC): Insights from the POTOMAC update and the role of durvalumab in high-risk, BCG-naive patients. Prostate Cancer: An overview of the DASL-HiCaP and PROTEUS studies, highlighting the use of androgen receptor pathway inhibitors (ARPIs) in earlier lines of treatment and their impact on metastasis-free survival (MFS). Renal Cell Carcinoma (RCC): Updates on KEYNOTE-564 and the LITESPARK studies, focusing on adjuvant therapies and the balance between efficacy and side effects.   Join us as we cut through the noise and focus on what is practice-changing in the field of oncology.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to subscribe for more insights and updates from the world of cancer research!   #ESMO2026, #GUOncology, #BladderCancer, #ProstateCancer, #KidneyCancer, #OncologyBrothers

    ESMO 2026 GU Highlights VOLGA, DASL-HiCAP, PROTEUS, KEYNOTE-564, LITESPARK-011

  2. Oct 22 ·  Video

    Multiple Myeloma CAR-T Management - Partners in Practice

    In this episode of the Oncology Brothers podcast, we dived deep into the complexities of second-line treatment options for multiple myeloma, with a special focus on CAR T-cell therapy. Joined by experts Dr. Rafael Fonseca, a multiple myeloma specialist from the Mayo Clinic; Dr. Beth Faiman, a nurse practitioner specializing in myeloma; and Ms. Carrie Bellerive, a clinical nurse coordinator at Memorial Sloan Kettering Cancer Center, the discussion covers:   The eligibility criteria for CAR T-cell therapy and the data supporting its effectiveness Insights from recent clinical trials, including CARTITUDE-1 and CARTITUDE-2, highlighting long-term outcomes and potential for cure The importance of patient preparation and shared decision-making in treatment planning The role of bridging therapy and the significance of managing disease burden prior to CAR T-cell infusion An overview of acute and chronic side effects associated with CAR T-cell therapy, including cytokine release syndrome (CRS) and neurotoxicity The critical coordination efforts behind the scenes to ensure seamless patient care   Join us as we explore how collaboration among healthcare professionals can enhance patient outcomes in the evolving landscape of multiple myeloma treatment.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/  Don't forget to like, subscribe, and share your thoughts in the comments! #MultipleMyeloma, #CARTtherapy, #BridgingTherapy, #HoldingTherapy, #OncologyBrothers

    Multiple Myeloma CAR-T Management - Partners in Practice

  3. Oct 19 ·  Video

    CAR-T Cell Therapy in Multiple Myeloma & Lymphoma - Clinical Foundations

    Welcome to the Oncology Brothers podcast! In this episode, we dived into the world of CAR T-cell therapy, featuring insights from hematology experts Drs. Luciano Costa and Shernan Holtan.   Join us as we explore: The basics of CAR T-cell therapy and the patient journey from referral to infusion The approved indications for CAR T-cell therapy in multiple myeloma and lymphoma, including the differences between idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) The importance of holding and bridging therapies to optimize patient outcomes The evolving landscape of side effects associated with CAR T-cell therapy, including acute and chronic effects Strategies for community oncologists to better manage patient care and improve access to CAR T-cell therapies   With the potential for curative outcomes in myeloma and lymphoma, understanding these therapies is crucial for both patients and healthcare providers. Tune in for an informative discussion that aims to bridge the gap between community oncology and specialized care.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers   •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest advancements in cancer treatment! #CARTtherapy, #MultipleMyeloma, #Lymphoma, #BridgingTherapy, #OncologyBrothers

    CAR-T Cell Therapy in Multiple Myeloma & Lymphoma - Clinical Foundations

  4. Oct 12 ·  Video

    Rapid Fire Rounds - Thrombocytopenia Workup & Management with Dr. Ronak Mistry

    Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Ronak Mistry, a hematologist from Penn Medicine, for a rapid-fire round addressing common questions about thrombocytopenia.   We dived into a variety of topics, including: Differentiating between inherited thrombocytopenia and mild immune thrombocytopenia (ITP) The role of steroids and bone marrow biopsy in diagnosis Management of anticoagulation in patients with low platelet counts Key distinctions between ITP, atypical hemolytic uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP) Recent updates to ITP guidelines and the incorporation of new treatment options Thrombocytopenia in pregnancy and its management Treatment options for chemotherapy-induced thrombocytopenia Common medications that may contribute to thrombocytopenia   Join us as we explore these important topics and provide practical insights for healthcare professionals dealing with thrombocytopenia in their clinical practice.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #Thrombocytopenia, #ITP, #TTP, #aHUS, #OncologyBrothers

    Rapid Fire Rounds - Thrombocytopenia Workup & Management with Dr. Ronak Mistry

  5. Oct 8 ·  Video

    Challenging Cases in Small Cell Lung Cancer (SCLC) - Drs. Estela Rodriguez & Misty Shields

    In this episode of the Oncology Brothers podcast, we dived into two challenging cases of small cell lung cancer (SCLC) to explore the latest supportive care options, the role of prophylactic cranial irradiation (PCI), and the sequencing of available treatments.   We were joined by Dr. Estela Rodriguez from the University of Miami and Dr. Misty Shields from the Indiana University, as they discussed: A young woman with limited-stage SCLC undergoing concurrent chemotherapy and radiation, and the management of treatment-related cytopenias The implications of the recent MAVERICK trial comparing MRI surveillance to PCI and its impact on patient care The evolving landscape of treatment options, including the use of trilaciclib and promising new therapies like tarlatamab and antibody-drug conjugates (ADCs) Insights into maintenance therapy and the importance of close monitoring for brain metastases   Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the management of small cell lung cancer.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o     Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in cancer care! #SmallCellLungCancer, #SCLC, #SupportiveCare, #MAVERICKtrial, #OncologyBrothers

    Challenging Cases in Small Cell Lung Cancer (SCLC) - Drs. Estela Rodriguez & Misty Shields

  6. Oct 5 ·  Video

    WCLC 2026 Highlights: MAVERICK, ADAURA, HARMONi, PAPILLON, DESTINY-Lung04 with Dr. Christine Lovly

    Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Christine Lovly, a thoracic medical oncologist from City of Hope, to discuss key studies presented at the World Conference on Lung Cancer 2026.   We dived into five pivotal studies, including: MAVERICK: study on the role of MRI surveillance in small cell lung cancer (SCLC), showing that prophylactic cranial irradiation (PCI) may no longer be necessary ADAURA Update: 8-year update continues to show benefit of adjuvant osimertinib for early-stage EGFR-mutant lung cancer, with an impressive overall survival (OS) benefit HARMONi: potential of ivonescimab, a PD-1 and VEGF bispecific antibody, in the treatment of EGFR-positive disease after progression on third-generation therapies PAPILLON: discussion on the frontline treatment options for EGFR exon 20 insertion mutations, including the role of amivantamab and the anticipated approval of sunvozertinib DESTINY-Lung04: an analysis of trastuzumab deruxtecan (T-DXd) in HER2-mutated lung cancer and its implications for treatment strategies   Join us as we explore the latest advancements in lung cancer treatment and the importance of biomarker testing. Don't miss this informative episode packed with insights for oncologists and healthcare professionals!   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Subscribe for more updates and discussions on the latest in oncology research and practice! #LungCancer, #WCLC2026, #Osimertinib, #Ivonescimab, #MAVERICK, #PAPILLON, #TDXd, #OncologyBrothers

    WCLC 2026 Highlights: MAVERICK, ADAURA, HARMONi, PAPILLON, DESTINY-Lung04 with Dr. Christine Lovly

  7. Sep 30 ·  Video

    Managing Toxicities of HER2+ Therapies in Upper GI Cancer - Trastuzumab, T-DXd, Zanidatamab

    Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in HER2-targeted therapies for upper gastrointestinal malignancies, with Drs. Shruti Patel and Samuel Cytryn.   Join us as we discussed: The recent approval of zanidatamab and its implications for HER2-positive esophageal and gastric adenocarcinoma The role of trastuzumab in treatment and its associated side effects, including cardiotoxicity and infusion reactions Addressing different dose used for trastuzumab deruxtecan (T-DXd) in upper GI space, along with important side effect profile to keep in mind The importance of shared decision-making in treatment options and the impact of dosing strategies on patient outcomes   We also covered the critical need for biomarker-driven treatment approaches, including HER2 status and PD-L1 scores, and how these factors influence therapy choices.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media:  ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Tune in for an informative discussion that bridges the gap between research and clinical practice, ensuring that patients receive the best care possible. Don't forget to like, subscribe, and hit the notification bell for more episodes! #HER2positive, #UpperGICancer, #Zanidatamab, #Trastuzumab, #TDXd, #OncologyBrothers

    Managing Toxicities of HER2+ Therapies in Upper GI Cancer - Trastuzumab, T-DXd, Zanidatamab

  8. Sep 28 ·  Video

    Upper GI Treatment Algorithm (Esophageal, Gastric, GEJ) - Dr. Sam Klempner

    Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Samuel Klempner, a GI medical oncologist from the Massachusetts General Hospital, to discuss the evolving treatment landscape for upper gastrointestinal cancers, specifically esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinoma.   During our discussion we touched on: The treatment algorithm for localized disease, including the shift from local therapy to a combination of systemic and local treatments The current standard of care, which includes perioperative durvalumab with the FLOT regimen and surgery The role of chemoradiation therapy for patients who are not surgical candidates and the nuances of managing residual disease The importance of biomarker-driven treatment in metastatic disease, focusing on HER2 status, PD-L1 scores, and CLDN18.2 expression The latest advancement, the approval of zanidatamab and clinical implications for treatment strategies Management of side effects associated with these therapies and the importance of patient quality of life   Whether you're a healthcare professional or someone interested in the latest in cancer care, this episode provides valuable insights into the complexities of treating upper GI cancers.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #UpperGICancer, #GastricCancer, #Zanidatamab, #Zolbetuximab, #OncologyBrothers

    Upper GI Treatment Algorithm (Esophageal, Gastric, GEJ) - Dr. Sam Klempner
See All (292)

4.9
out of 5
64 Ratings

About

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

Information

You Might Also Like